Cravath Reps Aptuit In $410M Deal With Catalent

Law360, New York (August 22, 2011, 12:34 PM EDT) -- Catalent Pharma Solutions Inc., flush with cash after having jettisoned its pharmaceutical printing business, announced Monday it would pay $410 million in cash for the clinical trial solutions business of Aptuit LLC.

Somerset N.J.-based Catalent said it would not incur any debt in making the purchase, which transforms it into the world's second-largest provider of clinical testing supplies and services behind Thermo Fisher Scientific Inc.

"This transaction builds important expertise, scale and capability," Catalent CEO John Chiminski said.

In May, Catalent, which employs approximately 9,000 people...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.